<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03254342</url>
  </required_header>
  <id_info>
    <org_study_id>28162</org_study_id>
    <nct_id>NCT03254342</nct_id>
  </id_info>
  <brief_title>MRS and Medication Response: A Pilot Study</brief_title>
  <official_title>Magnetic Resonance Spectroscopy and Medication Response: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration
      levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to demonstrate that it is feasible to image paroxetine
      (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) brain concentrations using MRS
      technology in depressed patients.

      The longer-term goal is to determine the relationship between clinically administered doses
      of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) (antidepressants), the
      amount of drug in the body via blood level, the concentrations of the drug achieved in brain
      measured via MRS, and genetics.

      It has been previously reported that individuals taking 20mg of paroxetine daily had brain
      paroxetine [(Paxil) levels via MRS ranging from 2-13 micromolar. Similar or slightly higher
      ranges of brain drug concentrations have been reported for fluoxetine and fluvoxamine.

      Since not all depressed patients respond to medications, one reason may be the amount of
      medication that crosses the blood-brain barrier. This may be influenced by genetic
      information. We want to examine these issues on a larger scale, but first we need to
      demonstrate that we can indeed determine paroxetine [(Paxil) or citalopram (Celexa) or
      escitalopram (Lexapro)] levels via MRS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2013</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 6, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of paroxetine (Paxil), citalopram (Celexa) or escitalopram (Lexapro) brain concentrations.</measure>
    <time_frame>Within 7 Days following MRS</time_frame>
    <description>Measurement of paroxetine (Paxil), citalopram (Celexa) or escitalopram (Lexapro) brain concentrations using MRS technology in depressed participants.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Major Depressive Episode</condition>
  <condition>Major Depressive Disorder, Recurrent</condition>
  <condition>Major Depression Mild</condition>
  <condition>Major Depression Moderate</condition>
  <condition>Major Depression Severe</condition>
  <arm_group>
    <arm_group_label>Major depressive disorder</arm_group_label>
    <description>There is no intervention/treatment in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-depressed individuals</arm_group_label>
    <description>There is no intervention/treatment in this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Psychiatry clinic; local community.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Major depressive disorder:

        Inclusion Criteria:

          1. DSM diagnosis of Major Depressive Disorder

          2. Taking paroxetine [(Paxil) or citalopram (Celexa) or escitalopram (Lexapro)]for at
             least 6 weeks

          3. Between 21 - 75 years of age.

          4. Taking a stable dose of paroxetine [(Paxil) or citalopram (Celexa) or escitalopram
             (Lexapro)] for at least the 2 weeks prior to the imaging session

        Healthy controls:

          1. Between 21 - 75 years of age.

          2. Have a 21-item HAM-D score of less than or equal to 5.

          3. No current, or history of any Axis I disorder.

        Identify exclusion criteria.

        Exclusion criteria are as follows:

          1. Contraindications for an MRI exam. These includes biomedical devices such as
             pacemakers, aneurysm clips, prostheses, and other metallic objects embedded in the
             body such as bullets, buckshot, shrapnel, and any metal fragments from working around
             metal.

          2. Current pregnancy or lactation.

          3. Patients with claustrophobia.

          4. History, or current Axis I or Axis II disorders

          5. Active unstable medical problems, as confirmed by screening procedures

          6. Diagnosed with any autoimmune disease, (e.g., rheumatoid arthritis, Lupus, MLS).

          7. Chronic use of steroids or opiates.

          8. Positive urine toxicology screen for illicit substances of abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MAUREEN H CHANG, BS</last_name>
    <phone>650-725-4620</phone>
    <email>MHCHANG@STANFORD.EDU</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JESSICA A HAWKINS, BA</last_name>
    <phone>650-723-8323</phone>
    <email>JHAWK@STANFORD.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Psychiatry and Biobehavioral Sciences</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen H Chang, BS</last_name>
      <phone>650-725-4620</phone>
      <email>mhchang@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica A Hawkins, BS</last_name>
      <phone>650-723-8323</phone>
      <email>jhawk@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alan Schatzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Alan Schatzberg</investigator_full_name>
    <investigator_title>Professor, Department of Psychiatry and Behavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Currently there is no plan.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

